UroGen Pharma (URGN) Retained Earnings (2016 - 2026)

UroGen Pharma (URGN) has 11 years of Retained Earnings data on file, last reported at -$983.3 million in Q1 2026.

• Quarterly Retained Earnings fell 15.67% year-over-year to -$983.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$983.3 million (down 15.67% YoY) and the FY2025 annual result came in at -$959.7 million, down 19.04% from the prior year.
• Retained Earnings fell to -$983.3 million in Q1 2026, from -$959.7 million in the prior quarter.
• In the past five years, Retained Earnings ranged from a high of -$495.7 million in Q1 2022 to a low of -$983.3 million in Q1 2026.
• A 5-year average of -$727.8 million and a median of -$711.6 million in 2024 frame the typical range for Retained Earnings.
• Annual changes were most pronounced in 2022 — Retained Earnings slipped 29.62% — and 2026, when it decreased 15.67%.
• Tracing URGN's Retained Earnings over 5 years: stood at -$577.1 million in 2022, then dropped by 17.72% to -$679.3 million in 2023, then decreased by 18.68% to -$806.2 million in 2024, then dropped by 19.04% to -$959.7 million in 2025, then declined by 2.46% to -$983.3 million in 2026.
• The last three Retained Earnings figures came in at -$983.3 million (Q1 2026), -$959.7 million (Q4 2025), and -$933.4 million (Q3 2025), per Business Quant data.